Holen Sie sich die Stockscreener-App
2.33
17.09%
0.34
Vorhandelsmarkt:
2.25
-0.08
-3.43%
Schlusskurs vom Vortag:
$1.99
Offen:
$2.26
24-Stunden-Volumen:
13.00M
Relative Volume:
9.34
Marktkapitalisierung:
$73.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-0.8381
EPS:
-2.78
Netto-Cashflow:
$-55.26M
1W Leistung:
+11.48%
1M Leistung:
+21.99%
6M Leistung:
+65.25%
1J Leistung:
-70.91%
1-Tages-Spanne:
$2.13
$2.46
1-Wochen-Bereich:
$1.88
$2.46
52-Wochen-Spanne:
$1.05
$8.74
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Vergleichen Sie ACRV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.33 | 62.60M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-31 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
Will Acrivon Therapeutics Inc. stock benefit from green energy trendsInflation Watch & Target Return Focused Picks - newser.com
Is Acrivon Therapeutics Inc. stock attractive for hedge fundsRecession Risk & Precise Buy Zone Tips - newser.com
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech
Is Acrivon Therapeutics Inc. stock a contrarian buyIPO Watch & Short-Term Swing Trade Alerts - newser.com
Is Acrivon Therapeutics Inc. stock supported by strong cash flows2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Will Acrivon Therapeutics Inc. stock split attract more investors2025 Trading Recap & Consistent Growth Stock Picks - newser.com
What high frequency data says about Acrivon Therapeutics Inc.Weekly Trend Recap & AI Driven Price Predictions - newser.com
Custom strategy builders for tracking Acrivon Therapeutics Inc.July 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Can Acrivon Therapeutics Inc. stock weather global recessionMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance
Why Acrivon Therapeutics Inc. stock is recommended by analystsJuly 2025 Closing Moves & Community Verified Trade Signals - newser.com
Will Acrivon Therapeutics Inc. rebound enough to break evenDip Buying & Free Reliable Trade Execution Plans - newser.com
Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications - TipRanks
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):